Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Weverling

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|July 20, 1996
Acute upper gastrointestinal haemorrhageA Verbon, G J Weverling
The Journal of Infectious Diseases|April 11, 2001
Timing of human immunodeficiency virus type 1 and human herpesvirus 8 infections and length of the Kaposi's sarcoma-free period in coinfected personsN Renwick, G J Weverling, T Schulz, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 24, 1996
[Computer-assisted education in problem-solving in neurology; a randomized educational study]G J Weverling, J Stam, T J ten Cate, et al.
Neurology|December 1, 1994
Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindredsB M van Geel, J Assies, G J Weverling, et al.
Journal of the Neurological Sciences|January 7, 1998
Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS ConsortiumE S Louwerse, C E Visser, P M Bossuyt, et al.
Clinical Pharmacology and Therapeutics|July 1, 1997
Circadian variations in serum levels and the renal toxicity of aminoglycosides in patientsJ M Prins, G J Weverling, R J van Ketel, et al.
Journal of the Neurological Sciences|May 1, 1995
Mortality risk stratification in amyotrophic lateral sclerosisE S Louwerse, P M Bossuyt, G J Weverling, et al.
Journal of the Neurological Sciences|May 1, 1995
Baseline assessments in amyotrophic lateral sclerosis trialsP M Bossuyt, E S Louwerse, G J Weverling, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2000
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study GroupE H Gisolf, C Dreezen, S A Danner, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1996
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapyJ M Prins, G J Weverling, K de Blok, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|July 20, 1996
Acute upper gastrointestinal haemorrhageA Verbon, G J Weverling
The Journal of Infectious Diseases|April 11, 2001
Timing of human immunodeficiency virus type 1 and human herpesvirus 8 infections and length of the Kaposi's sarcoma-free period in coinfected personsN Renwick, G J Weverling, T Schulz, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 24, 1996
[Computer-assisted education in problem-solving in neurology; a randomized educational study]G J Weverling, J Stam, T J ten Cate, et al.
Neurology|December 1, 1994
Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindredsB M van Geel, J Assies, G J Weverling, et al.
Journal of the Neurological Sciences|January 7, 1998
Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS ConsortiumE S Louwerse, C E Visser, P M Bossuyt, et al.
Clinical Pharmacology and Therapeutics|July 1, 1997
Circadian variations in serum levels and the renal toxicity of aminoglycosides in patientsJ M Prins, G J Weverling, R J van Ketel, et al.
Journal of the Neurological Sciences|May 1, 1995
Mortality risk stratification in amyotrophic lateral sclerosisE S Louwerse, P M Bossuyt, G J Weverling, et al.
Journal of the Neurological Sciences|May 1, 1995
Baseline assessments in amyotrophic lateral sclerosis trialsP M Bossuyt, E S Louwerse, G J Weverling, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 14, 2000
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study GroupE H Gisolf, C Dreezen, S A Danner, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1996
Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapyJ M Prins, G J Weverling, K de Blok, et al.
Pageof 7